Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Other: Prospective observational cohort study

Study type: Observational

Funder types: Industry

Identifiers

NCT04853238

213550

Details and patient eligibility

About

This observational study will be conducted in COPD participants in Tier 2 and 3 hospitals in China to gain an understanding of the complex COPD management and physician's treatment strategy.

Enrollment: 1,507 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female participants with minimum 40 years of age.
• A diagnosis of COPD confirmed by spirometry (According to Global initiative for chronic obstructive lung disease [GOLD] 2019 criteria) in Tier 2 and Tier 3 hospitals.
• In hospitalized participants, recruit only participants who receive any intravenous therapy.
• A signed and dated written informed consent.
• Participants can communicate normally.

Exclusion criteria

• Current primary diagnosis of asthma, active tuberculosis, bronchiectasis, lung cancer or other active pulmonary disease.
• Other unstable diseases or cognitive behavior, which could influence CAT and lung function results (judged by physicians).
• Experienced a moderate/severe COPD exacerbation treated by a physician within last 1 month.
• Currently participating in another COPD clinical study, which provides the participant investigational medication and/or disease management.

Trial design

1,507 participants in 3 patient groups

Cohort 1: Participants with stable disease

Treatment:

Other: Prospective observational cohort study

Cohort 2: Participants with moderate acute exacerbation not requiring hospitalization

Treatment:

Other: Prospective observational cohort study

Cohort 3: Participants requiring hospitalization for an acute exacerbation

Treatment:

Other: Prospective observational cohort study